GGHC
LAB icon

Gilder Gagnon Howe & Co’s Standard BioTools LAB Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-11,138
Closed -$491K – 316
2014
Q1 		$491K Buy
+11,138
New +$490K 0.01% 229

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Gilder Gagnon Howe & Co's LAB Position: Q2 2014 in Review

Gilder Gagnon Howe & Co sold out of Standard BioTools (LAB) in Q2 2014, closing a stake of 11,138 shares — an estimated $491K sold.

Gilder Gagnon Howe & Co first reported a position in LAB in Q1 2014 and held it in 1 quarter. The position peaked at $491K in Q1 2014. 104 funds tracked by Wall St. Rank hold LAB as of Q2 2014.

  • Gilder Gagnon Howe & Co reported no remaining Standard BioTools position as of Q2 2014 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 11,138 Standard BioTools shares in Q2 2014, an estimated $491K.
  • Gilder Gagnon Howe & Co first reported a position in Standard BioTools in Q1 2014 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Standard BioTools position peaked at $491K in Q1 2014.
  • 104 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2014.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2014, filed 1 Aug 2014.